PRRT2 and plasma cell myeloma: In fact, we found that very dissimilar leukemic cell lines (B-ALL, T-ALL, CML, multiple myeloma), were severely affected by a 2 h treatment with 40 μM HKPS, a chimeric peptide able to penetrate cells and inhibit PKC activity [29].